Sánchez-Hernández JA, Gutiérrez-Fernández EC, Pérez TR, Cedillo-Ramírez L, Rivera-Tapia JA

Language: Spanish
References: 13
Page: 31-35
PDF size: 289.33 Kb.

ABSTRACT

HIV continues its global spread to at least 40 million people infected worldwide. Moreover, the human papilloma virus is the most common sexually transmitted viral infection in humans and is considered the major etiologic agent of cervical cancer. In recent years there has been a considerable increase in patients who get these diseases and more serious still that continue reporting more cases of patients presenting with both diseases at the same time, which significantly increases the possibility of changing the course clinical disease becoming a potential risk for the development of other diseases such as anorectal cancer and cervical cancer that have become major causes of death in Mexico. It has also been shown to have both diseases seems to have a negative effect on human immunity as noteworthy changes occur during the course of these conditions as the CD4 count is affected. The objective of this work was analyze patients with both HIV and HPV and its influence on CD4 cell count as the developing both diseases can change the clinical course of the same and significantly affect human immunity. Forty HIV positive patients confirmed by Western blot by General Hospital, Puebla and Cellular Biology Laboratory of Medicine Faculty of Benemérita Universidad Autónoma de Puebla, México; to which were also made making cells were investigated cervical-vaginal (Pap), the samples were processed with the technique of modified Papanicolaou stain, plus citobrush samples taken for RC and determine what types of HPV coexisted with HIV. They were also made to CD4 cell count patients for further analysis and comparison. Five HPV-positive and CD4 values ​​within normal limits 9 HPV-negative patients and decreased CD4 counts and 26 HPV-positive patients with decreased CD4 cell count patients and 12 HPV-positive patients revealed the presence of koilocytes in exfoliative cytology. In conclusion, we conclude that patients with both diseases are more likely to suffer a significant drop in cellular immunity despite retroviral therapy and makes them susceptible to other diseases and acquire a lower count to 200 CD4 cells per cubic mL reveal significant damage to the immune system.

REFERENCES

1. Ayers LW, Silver S, McGrath M, Orenstien JM. The AIDS and cancer specimen resource: role in HIV/AIDS scientific discovery. Infect Agent Cancer. 2007; 2: 2-7.

2. Ng’andwe C, Lowe JJ, Richards PJ, Hause L, Wood C, Angeletti PC. The distribution of sexually-transmitted human papillomaviruses in HIV positive and negative patients in Zambia. Africa. BMC Infect Dis. 2007; 7: 67-77.

3. Sirera G, Videla S, Herranz P, Corzo-Delgado JE. Virus del papiloma humano y virus de la inmunodeficiencia humana/sida. Enf Infec Microbiol Clin. 2006; 24 (Supl 2): 40-46.

4. Clarke B, Chetty R. Postmodern cancer: the role of human immunodeficiency virus in uterine cervical cancer. Mol Pathol. 2002; 55: 19-24.

5. Zarco OC, Postigo LC, Llamas MR, Suárez MA, Picazo de la Garza J, Castaño SE y cols. Detección y tipado de Papilomavirus humano en raspados de pacientes infectados por el virus de inmunodeficiencia humana. Actas Dermosifiliogr. 2003; 94: 17-23.

6. Hameed M, Fernandes H, Skurnick J, Moore D, Kloser P, Heller D. Human papillomavirus typing in HIV-positive women. Infect Dis Obstet Gynecol. 2001; 9: 89-93.

7. Sánchez HJ, Varela SO, Gómez LC, Islas DG, Pezzad SE, Martínez HJ et al. Relación entre VIH y VPH estudio de 40 casos. Revista UAS. 2011; 2: 45-49.

8. Sobel JD. Gynecologic infections in human immunodeficiency virus-infected women. Clin Infect Dis. 2000; 31: 1225-1233.

9. Ferenczy A, Coutlée F, Franco E, Hankins C. Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract. CMAJ. 2003; 169: 431-434.

10. Gonçalves MA, Soares EG, Donadi E. The influence of human papillomavirus type and HIV status on the lymphomononuclear cell profile in patients with cervical intraepithelial lesions of different severity. Infec Agent Cancer. 2009; 4: 11-16.

11. Villanueva P, Díaz P, Guido M, Rangel A, Sotelo R, García-Carranca A. Prevalencia de virus de papiloma humano de alto riesgo en el epitelio anal de hombres VIH positivos. Bioquimia. 2002; 27: 94-102.

12. Höpfl R, Petter A, Thaler P, Sarcletti M, Widschwendter A, Zangerle R. High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study. BMC Infect Dis. 2003; 3: 6.

13. Montoya GCJ, Moreno FE, Rugeles LT. Reacciones y alteraciones del sistema inmune durante la infección por el VIH-1. Infectio. 2006; 10: 250-265.